SS Innovations International (NASDAQ:SSII – Get Free Report) and Pulmonx (NASDAQ:LUNG – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.
Valuation & Earnings
This table compares SS Innovations International and Pulmonx”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SS Innovations International | $42.49 million | 11.49 | -$12.13 million | ($0.06) | -40.60 |
| Pulmonx | $90.50 million | 1.41 | -$54.00 million | ($1.01) | -2.95 |
Insider and Institutional Ownership
91.0% of Pulmonx shares are owned by institutional investors. 7.5% of Pulmonx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for SS Innovations International and Pulmonx, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SS Innovations International | 1 | 0 | 0 | 0 | 1.00 |
| Pulmonx | 1 | 0 | 3 | 0 | 2.50 |
SS Innovations International currently has a consensus target price of $7.00, indicating a potential upside of 187.36%. Pulmonx has a consensus target price of $7.67, indicating a potential upside of 157.70%. Given SS Innovations International’s higher possible upside, equities research analysts plainly believe SS Innovations International is more favorable than Pulmonx.
Risk & Volatility
SS Innovations International has a beta of -1.51, meaning that its stock price is 251% less volatile than the S&P 500. Comparatively, Pulmonx has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500.
Profitability
This table compares SS Innovations International and Pulmonx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SS Innovations International | -23.73% | -26.77% | -15.01% |
| Pulmonx | -47.93% | -91.79% | -35.07% |
About SS Innovations International
AVRA Medical Robotics, Inc. develops and manufactures medical surgical devices. The company has a research agreement with the University of Central Florida to develop navigation and control technologies with applications in medical robotics. The company was formerly known as AVRA Surgical Microsystems, Inc. and changed its name to AVRA Medical Robotics, Inc. in November 2015. AVRA Medical Robotics, Inc. was founded in 2015 and is based in Orlando, Florida.
About Pulmonx
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Receive News & Ratings for SS Innovations International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SS Innovations International and related companies with MarketBeat.com's FREE daily email newsletter.
